News

This final closing includes new strategic investments from AbbVie, WuXi PharmaTech, and Watson Fund. These new investors join the previously announced Accelerator IV syndicate, which includes Alexandria Venture

Enobosarm, a selective androgen receptor modulator (SARM), is the Company’s lead product candidate. GTx executive chairman Robert Wills said: "Additional endocrine directed therapies are needed for the treatment

The transaction was led by Rock Springs Capital Management and included other leading healthcare investors such as Fidelity Management and Research Company, Blackrock, funds, accounts managed by T.

The Johnson & Johnson Innovation Center in California facilitated the research agreement on behalf of the Janssen Disease Interception Accelerator. Under the terms of the agreement, UbiVac will

In July last year, the EC granted orphan designation for beloranib to treat Prader-Willi syndrome (PWS). Beloranib is being studied as a first-in-class obesity therapy that shows a

The product will be commercialized in Japan by Takeda Pharmaceutical Company Limited (Takeda). In Japan, glatiramer acetate was developed as an Unapproved New Drug by Teva Pharmaceutical K.K.,

The tender offer, which is due to expire on 27 October, was made through Sun Pharma’s subsidiary Thea Acquisition for all of InSite Vision’s outstanding shares of common

The prosthesis features a small array of electrodes implanted into the brain. Scientists are evaluating it in human patients after its successful laboratory testing in animals. After receiving

Under the trial, Mesoblast carried out a post-hoc analysis in 30 patients who were randomized to receive either placebo or a single administration of 150 million MPCs (MPC-150-IM).